RenovoRx (RNXT) EPS (Basic) (2020 - 2026)

RenovoRx (RNXT) posted EPS (Basic) of -$0.09 for Q1 2026, up 8.15% sequentially from -$0.1 in Q4 2025, and up 16.08% YoY from -$0.08 in Q1 2025.

RenovoRx (RNXT) EPS (Basic) (2020 - 2026) Analysis & Trends

RenovoRx has reported EPS (Basic) for 7 years, with the latest figure at -$0.09 in Q1 2026.

Quarterly EPS (Basic) rose 16.08% year-over-year to -$0.09 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.39 (up 58.33% YoY) and the FY2025 annual result came in at -$0.91, up 26.62% from the prior year.
EPS (Basic) improved to -$0.09 in Q1 2026 per RNXT's latest filing, from -$0.1 in the prior quarter.
Over five years, EPS (Basic) peaked at -$0.09 in Q1 2026 and troughed at -$0.87 in Q4 2024.
A 5-year average of -$0.29 and a median of -$0.26 in 2023 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2024 and 2025: EPS (Basic) tumbled 229.24% in 2024, then soared 88.57% in 2025.
Over 5 years, EPS (Basic) stood at -$0.34 in 2022, then rose by 22.63% to -$0.26 in 2023, then sank by 229.24% to -$0.87 in 2024, then jumped by 88.57% to -$0.1 in 2025, then advanced by 8.15% to -$0.09 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.09, -$0.1, and -$0.11 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	139.82 Bn	131.97 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	86.70 Bn	78.71 Bn	3.93 Bn	12.62
3	Argenx Se	65.27 Bn	60.09 Bn	1.37 Bn	7.59
4	Moderna	59.18 Bn	54.04 Bn	52.00 Mn	-1.96
5	BeOne Medicines	42.11 Bn	37.01 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	31.80 Bn	28.49 Bn	992.69 Mn	1.23
7	BioNTech SE	28.14 Bn	9.75 Bn	668.28 Mn	-0.72
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn	-0.06
9	Royalty Pharma	27.26 Bn	26.42 Bn	-	0.18
10	RenovoRx	62.20 Mn	62.20 Mn	766,000.00	-0.07

Download Data